Highly selective bradykinin agonists and antagonists with replacement of proline residues by N-methyl-D- and L-phenylalanine

Journal of Medicinal Chemistry

Volumn 39, Issue 4, 1996, Pages 929-936

  Reissmann, Siegmund ^a   Schwuchow, Carola ^a   Seyfarth, Lydia ^a   De Castro, Luis Felipe Pineda ^a   Liebmann, Claus ^a   Paegelow, Inge ^b   Werner, Heinz ^b   Stewart, John M ^c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ ANTAGONIST; BRADYKININ B2 RECEPTOR; BRADYKININ RECEPTOR AGONIST; BRADYKININ[2 N METHYLPHENYLALANINE]; CYTOKINE; N METHYL DEXTRO PHENYLALANINE; N METHYL LEVO PHENYLALANINE; PHENYLALANINE; PROLINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; GUINEA PIG; ILEUM; LUNG PARENCHYMA; MONONUCLEAR CELL; MOUSE; NONHUMAN; RAT; SPLEEN CELL; UTERUS;

AMINO ACID SEQUENCE; ANIMALS; BRADYKININ; CELL MEMBRANE; FEMALE; GUINEA PIGS; ILEUM; INDICATORS AND REAGENTS; MALE; MOLECULAR SEQUENCE DATA; MUSCLE, SMOOTH; PHENYLALANINE; PROLINE; PROTEIN CONFORMATION; RATS; RECEPTORS, BRADYKININ; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; UTERUS;

EID: 0030066121     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9301954     Document Type: Article

References (57)

1. 8]BK; ia, intraarterial; iv, intravenous; LS, lung strip; Mts, mesitylene-2-sulfonyl; NMF, N-methyl-Phe; Oic, octahydroindole-2-carboxylic acid; DPhe(Cl), p-chloro-D-Phe; ΔPhe, 2,3-dehydro-Phe; PyBrop, bromotrispyrrolidinophosphonium hexafluorophosphate; RUT, rat uterus; TBTU, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate; TEEM, tanned erythrocyte electrophoretic mobility; TES, N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid; TFA, trifluoroacetic acid; TFMSA, trifluoromethanesulfonic acid; Tic, tetrahydroisoquinoline-3-carboxylic acid; Thi, β-2-thienylalanine; Tos, p-toluenesulfonyl.
2. Regoli, D.; Barabe, J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 1980, 32, 1-46.
3. Bhoola, K. D.; Figueroa, C D.; Worthy, K. Bioregulation of kinins: kallikrein, kininogens, and related kininases. Pharmacol. Rev. 1992, 44, 1-78.
4. Dray, A.; Perkins, M. Bradykinin and inflammatory pain. Trends Neurosci. 1993, 16, 99-104.
5. Chau, T. T.; Lewin, A. C.; Walter, T. L.; Carlson, R. P.; Weichmann, B. M. Evidence for a role of bradykinin in experimental pain models. Agents Actions 1991, 34, 235-238.
6. Burch, R. M.; Kyle, D. J. Minireview: Recent developments in the understanding of bradykinin receptors. Life Sci. 1992, 50, 829-838.
7. (a) Steranka, L. R.; Manning, D. C.; de Haas, C. J.; Ferkany, J. W.; Borosky, S. A.; Connor, J. R.; Vavrek, R. J.; Stewart, J. M.; Snyder, S. H. Bradykinin as pain mediator: receptors are localized to sensory neurons and antagonists have analgesic effects. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 3245-3249.
8. (b) Stewart, J. M. The kinin system in inflammation. Agents Actions 1993, 42S, 145-147.
9. Vavrek, R. J.; Stewart, J. M. Competitive antagonists of bradykinin. Peptides 1985, 6, 161-164.
10. 2 bradykinin antagonists. In Bradykinin Antagonists. Basic and Clinical Research; Burch, R. M., Ed.; Marcel Dekker, Inc.: New York, 1991; pp 51-96.
11. Regoli, D.; Rhaleb, N. E.; Dion, S.; Drapeau, G. New selective bradykinin antagonists and bradykinin 82 receptor characterization. Trends Pharmacol. Sci. 1990, 11, 156-161.
12. Cheronis, J. C.; Whalley, E. T.; Nguyen, K. T.; Eubanks, S. R.; Allen, L. G.; Duggan, M. J.; Loy, S. D.; Bonham, K. A.; Blodgett, J. K. A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J. Med. Chem. 1992, 35, 1563-1572.
13. Lembeck, F.; Griesbacher, T.; Eckhardt, M.; Henke, St.; Breipohl, G.; Knolle, J. New, long-acting, potent bradykinin antagonists. Br. J. Pharmacol. 1991, 102, 297-304.
14. Kyle, D. J.; Martin, J. A.; Burch, R. M.; Carter, J. P.; Lu, S.; Meeker, S.; Prosser, J. C.; Sullivan, J. P.; Noronha-Blob, J. T. L.; Sinsko, J. A.; Walters, R. F.; Whaley, L. W.; Hiner, R. N. Probing the bradykinin receptor: mapping the geometric topography using ethers of hydroxyproline in novel peptides. J. Med. Chem. 1991, 34, 2649-53.
15. (a) Kyle, D. J.; Hicks, R. P.; Blake, P. R.; Klimkowski, V. J. Conformational properties of bradykinin and bradykinin antagonists. In Bradykinin Antagonists: Basic and Clinical Research; Burch, R. M., Ed.; Marcel Dekker: New York, 1990; pp 131-146.
16. (b) Kyle, D. J.; Martin, J. A.; Farmer, St. G.; Burch, R. M. Design and Conformational analysis of several highly potent bradykinin receptor antagonists. J. Med. Chem. 1991, 34, 1230-1233.
17. (c) Kyle, D. J.; Blake, P. R.; Smithwick, D.; Green, L. M.; Martin, J. A.; Sinsko, J. A.; Summers, M. F. NMR and computational evidence that high-affinity bradykinin receptor antagonists adopt C-terminal β-turns. J. Med. Chem. 1993, 36, 1450-1460.
18. (d) Chaturvedi, S.; Wilkens, D.; Kyle, D. J. Design of potent, cyclic peptide bradykinin receptor antagonists from conformationally constrained linear peptides. J. Med. Chem. 1993, 36, 2569-2571.
19. (a) Liu, X.; Stewart, J. M.; Gera, L.; Kotovych, G. Proton magnetic resonance studies of bradykinin antagonists. Biopolymers 1993, 33, 1237-1247.
20. (b) Otter, A.; Bigler, P.; Stewart, J. M.; Kotovych, G. A proton magnetic resonance study of two synthetic agonist-antagonist pairs of bradykinin analogues. Biopolymers 1993, 33, 769-780.
21. Momany, F. A. Conformational analysis and polypeptide drug design. Top. Curr. Phys. 1981, 26, 41-79.
22. 4]-enkephalins. Int. J. Pept. Protein Res. 1993, 41, 261-274.
23. (a) Tonelli, A. E.; The effects of isolated N-methylated residues on the conformational characteristics of polypeptides. Biopolymers. 1976, 15, 1615-1622.
24. (b) Manavalan, P.; Momany, F. A. Conformational energy studies on N-methylated analogs of thyrotropin releasing hormone, enkephalin, and luteinizing hormone-releasing hormone. Biopolymers 1980, 19, 1943-1973.
25. Vitoux, B.; Aubry, A.; Cung, M. T.; Marraud, M. N-methyl peptides. Int. J. Pept. Protein Res. 1986, 27, 617-632.
26. 28 31]-CCK(26-33): Synthesis, activity, and receptor selectivity. J. Med. Chem. 1992, 35, 2806-2811.
27. Haviv, F.; Fitzpatrick, T. D.; Swenson, R. E.; Nichols, C. J.; Mort, N. A.; Bush, E. N.; Diaz, G.; Bammert, G.; Nguyen, A.; Rhutasel, N. S.; Nellans, H. N.; Hoffmann, D. J.; Johnson, E. S.; Greer, J. Effect of N-methyl substitution of the peptide bonds in luteinizing hormone-releasing hormone agonists. J. Med. Chem. 1993, 36, 363-389.
28. Filatova, M. P.; Krit, N. A.; Beschastnaya, N. V.; Reissmann, S. Synthesis of new bradykinin analogs with modified peptide chain. Bioorg. Khim. 1979, 5, 1445-1454.
29. Boissonnas, R. A.; Guttmann, S.; Jaquenoud, P.-A. Synthese de la L-arginyl-L-prolyl-L-prolyl-glycyl-L-phenylanyl-L-seryl-L-prolyl-L-phenylalanyl- L-arginine, un nonapeptide presentant les propreietes de la bradykinine. (Synthesis of L-arginyl-L-prolyl-L-prolyl-glycyl-L-phenylalanyl-L-seryl-L-prolyl-L- phenylalanyl-L-arginine, a nonapeptide presenting the properties of bradykinin.) Helv. Chim. Acta 1960, 43, 1349-1358.
30. Merrifield, R. B. Solid phase peptide synthesis: II. The synthesis of bradykinin. J. Am. Chem. Soc. 1964, 86, 304-305.
31. Farmer, S. G.; Burch, R. M. Biochemical and molecular pharmacology of kinin receptors. Annu. Rev. Pharmacol. Toxicol. 1992, 32, 511-36.
32. Hall, J. M. Bradykinin receptors: pharmacological properties and biological roles. Pharm. Ther. 1992, 56, 131-190.
33. Regoli, D.; Jukic, D.; Toussignant, C.; Rhaleb, N.-E. Kinin receptor classification. In Recent Progress on Kinins; Fritz, H., Müller-Esterl, W., Jochum, M., Roscher, A., Luppertz, K., Eds.; Birkhäuser Verlag: Basel, 1992; pp 475-486. (Agents Actions 38/SI).
34. (a) Paegelow, II; Werner, H.; Reissmann, S. Effects of bradykinin and bradykinin analogues on spleen cells of mice. Eur. J. Pharmacol. 1995, 279, 211-216.
35. (b) Werner, H. Investigations of interleukins (IL-1, IL-2) using particle electrophoretic mobility. In Electrophoresis 86; Dunn, M. J., Ed.; VCH Verlagsgesellschaft: Weinheim, 1986; pp 61-64.
36. Tobler, H. J.; Engel, G. Affinity spectra: a novel way for the evaluation of equilibrium binding experiments. Naunyn-Schmiedebergapos Arch. Pharmacol. 1983, 322, 183-192.
37. Stewart, J. M.; Klis, W. A. Polystyrene-based solid phase peptide synthesis: the state of the art. In Solid Phase Synthesis; Epton, R., Ed.; SPCC (UK) Ltd.: Birmingham, 1990; pp 1-9.
38. Mazur, R. H.; James, P. A.; Tyner, D. A.; Hallinan, E. A.; Sanner, J. H.; Schulze, R. Bradykinin analogues containing N-methyl amino acids. J. Med. Chem. 1980, 23, 758-763.
39. 7-substituted peptide bradykinin antagonists are not substrates for kininase II. Peptides 1989, 10, 109-112.
40. (a) Farmer, S. G.; Burch, R. M.; Meeker, S. A.; Wilkins, D. E. Evidence for a pulmonary B3 bradykinin receptor. Mol. Pharmacol. 1989, 36, 1-8.
41. (b) Mak, J. C. W.; Barnes, P. J. Autoradiographic visualization of bradykinin receptors in human and guinea pig lung. Eur. J. Pharmacol. 1991, 194, 37-43.
42. Schröder, E. Structure-activity relationships in kinins. In Handbook of Experimental Pharmacology; Erdös, E. G., Ed.; Springer-Verlag: Heidelberg, 1970; Vol. XXV, pp 324-350.
43. Stewart, J. M. Chemistry and biological activity of peptides related to bradykinin. In Handbook of Experimental Pharmacology; Erdös, E. G., Ed.; Springer-Verlag: Heidelberg, 1979; Vol. XXV (Suppl.), pp 227-272.
44. 7]-substituted analogs of bradykinin inhibit vasopressin- and bradykinin-induced contraction of uterine smooth muscle. J. Pharmacol. Exp. Ther. 1989, 248, 677-681.
45. (a) Manning, D. C.; Vavrek, R.; Stewart, J. M.; Snyder, S. H. Two bradykinin binding sites with picomolar affinities. J. Pharmacol. Exp. Ther. 1986, 237, 504-512.
46. 2-family, Biochem. Biophys. Res. Commun. 1990, 167, 910-917.
47. 2 bradykinin receptors in rat myometrial membranes. Eur. J. Pharmacol. 1991, 199, 363-365.
48. Ransom, R. W.; Goodman, C. B.; Young, G. S.; Bradykinin stimulation of phosphoinositide hydrolysis in guinea-pig ileum longitudinal muscle. Br. J. Pharmacol. 1992, 105, 919-924.
49. 2 receptor. Eur. J. Pharmacol. 1994, 288, 35-43.
50. Liebmann, C.; Bosse, R.; Escher, E. Discrimination between putative bradykinin B2 receptor subtypes in guinea pig ileum smooth muscle membranes with a selective, iodinatable, bradykinin analogue. Mol. Pharmacol. 1994, 46, 949-956.
51. Pesquero, J. B.; Lindsey, C. J.; Zeh, K.; Paiva, A. C. M.; Ganten, D.; Bader, M. Molecular structure and expression of rat bradykinin B2 receptor gene. Evidence for alternative splicing. J. Biol. Chem. 1994, 269, 26920-26925.
52. Olsen, R. K. A convenient synthesis of protected N-methylamino acid derivatives. J. Org. Chem. 1970, 35, 1912-1915.
53. 2 receptor antagonist, Hoe 140, in the rat uterus. Eur. J. Pharmacol. 1993, 255, 183-188.
54. Schnitttler, M.; Liebmann, C.; Opfermann, J. Experimentelles Design and Auswertung von Radioliganden-Bindungsstudien. (Experimental design and evaluation of radioligand-binding studies.) Pharmazie 1991, 46, 2-8.
55. Schild, H. O. A method of conducting a biological assay on a preparation giving repeated graded responses illustrated by the estimation of histamine. J. Physiol. 1942, 101, 115.
56. Van Rossum, J. M.; van Hurkmans, J. A. Th. M.; Wolters, C. J. J. Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch. Int. Pharmacodyn. 1963, 143, 299-330.
57. Siems, W.-E.; Heder, G.; Komissarova, N. W. Verfahren zur Bestimmung des Angiotensin-Converting Enzyms. (Procedure for measurement of angiotensin-converting enzyme.) Z. Med. Lab. Diagn. 1985, 26, 230.